EPO and neoplasm: Statistical analysis showed significant increase of tumor MVD in erythropoietin-treated DLD-1 xenografts compared with control DLD-1 xenografts (p < 0.05) and compared with Ht-29 xenografts (p < 0.001), as well as in control DLD-1 xenografts compared with Ht-29 xenografts (p < 0.005).